EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Performance of CHA2DS2-VASc and HAS-BLED in predicting stroke and bleeding in atrial fibrillation and cancer

Alyaa M Ajabnoor iD, Salwa S Zghebi iD, Rosa Parisi iD, Darren M Ashcroft iD, Corinne Faivre-Finn iD, Mamas A Mamas iD, Evangelos Kontopantelis iD

European Heart Journal Open · 06.07.2024 · 4 (4)

DOI: 10.1093/ehjopen/oeae053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Heart Journal Open, online erschienen am 26.06.2024. Verfasst von Alyaa M Ajabnoor und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, P.O. Box 80324, Jeddah 21589, Saudi Arabia. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AMA research, Ministry of Education, University of Manchester.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To compare the predictive performance of CHA2DS2-VASc and HAS-BLED scores in atrial fibrillation (AF) patients with and without cancer. Methods and results Using data from the Clinical Practice Research Datalink in England, we performed a retrospective cohort study of patients with new diagnoses of AF from 2009 to 2019. Cancer was defined as history of breast, prostate, colorectal, lung, or haematological cancer. We calculated the CHA2DS2-VASc and HAS-BLED scores for the 1-year risk of stroke and major bleeding events. Scores performance was estimated by discrimination [area under the receiver operating characteristic curve (AUC)] and calibration plots. Of 141 796 patients with AF, 10.3% had cancer. The CHA2DS2-VASc score had good to modest discrimination in prostate cancer AUC = 0.74 (95% confidence interval: 0.71, 0.77), haematological cancer AUC = 0.71 (0.66, 0.76), colorectal cancer AUC = 0.70 (0.66, 0.75), breast cancer AUC = 0.70 (0.66, 0.74), and lung cancer AUC = 0.69 (0.60, 0.79), compared with no-cancer AUC = 0.73 (0.72, 0.74). HAS-BLED discrimination was poor in prostate cancer AUC = 0.58 (0.55, 0.61), haematological cancer AUC = 0.59 (0.55, 0.64), colorectal cancer AUC = 0.57 (0.53, 0.61), breast cancer AUC = 0.56 (0.52, 0.61), and lung cancer AUC = 0.59 (0.51, 0.67), compared with no-cancer AUC = 0.61 (0.60, 0.62). Both the CHA2DS2-VASc score and HAS-BLED score were well calibrated across all study cohorts.

Conclusion

Amongst certain cancer cohorts in the AF population, CHA2DS2-VASc performs similarly in predicting stroke to AF patients without cancer. Our findings highlight the importance of cancer diagnosis during the development of risk scores and opportunities to optimize the HAS-BLED risk score to better serve cancer patients with AF.

Schlagwörter

Stichwörter der Autor:innen

Atrial fibrillationBleedingCancerOral anticoagulantRisk assessment scoreStroke

Autor:innen und Institutionen

  • Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, P.O. Box 80324, Jeddah 21589, Saudi Arabia.
  • Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre (MAHSC), University of Manchester, Manchester M13 9PL, UK.
  • Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre (MAHSC), University of Manchester,…
  • Division of Pharmacy and Optometry, Centre for Pharmacoepidemiology and Drug Safety, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, UK.
  • National Institute for Health and Care Research (NIHR) Greater Manchester Patient Safety Research Collaboration (PSRC), University of Manchester, Manchester M13 9PL, UK.
  • The Christie NHS Foundation Trust and The University of Manchester, Manchester, UK.

ORCID-Profile: Alyaa M Ajabnoor, Salwa S Zghebi, Rosa Parisi, Darren M Ashcroft, Corinne Faivre-Finn, Mamas A Mamas, Evangelos Kontopantelis

Förderung

  • AMA research
  • Ministry of Education
  • University of Manchester
  • National Institute of Health and Care Research
  • NIHR Greater Manchester Patient Safety Translational Research Centre

Zitieren

APA

Ajabnoor, A. M., Zghebi, S. S., Parisi, R., Ashcroft, D. M., Faivre-Finn, C., Mamas, M. A., & Kontopantelis, E. (2024). Performance of CHA2DS2-VASc and HAS-BLED in predicting stroke and bleeding in atrial fibrillation and cancer. European Heart Journal Open, 4(4). https://doi.org/10.1093/ehjopen/oeae053

Vancouver

Ajabnoor AM, Zghebi SS, Parisi R, Ashcroft DM, Faivre-Finn C, Mamas MA, et al. Performance of CHA2DS2-VASc and HAS-BLED in predicting stroke and bleeding in atrial fibrillation and cancer. European Heart Journal Open. 2024;4(4). doi:10.1093/ehjopen/oeae053

BibTeX
@article{Ajabnoor2024,
  author = {Ajabnoor, Alyaa M and Zghebi, Salwa S and Parisi, Rosa and Ashcroft, Darren M and Faivre-Finn, Corinne and Mamas, Mamas A and Kontopantelis, Evangelos},
  title = {Performance of CHA2DS2-VASc and HAS-BLED in predicting stroke and bleeding in atrial fibrillation and cancer},
  journal = {European Heart Journal Open},
  year = {2024},
  volume = {4},
  number = {4},
  doi = {10.1093/ehjopen/oeae053}
}
Kostenlos starten →